Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 7, 2026

Google, Meta and the AI ‘hyperscalers’ are on a $1 trillion borrowing binge after years of printing cash. Here’s why Big Tech’s pivot to debt matters

View original at finance.yahoo.com
Google, Meta and the AI ‘hyperscalers’ are on a $1 trillion borrowing binge after years of printing cash. Here’s why Big Tech’s pivot to debt matters Almost every major capital spending boom during the past 200 years has ended in bankruptcies, consolidations, and tears—but also wins for the victors…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The issue for us is the spreads are very, very tight. And as you go longer, there's not much of a yield pickup at all

    80% confidence
  • You only find out after the fact. If you start to see it ahead of time, then others see it too, and investment starts to slow down on its own

    80% confidence
  • In an asset-light model, you tend to have higher equity multiples, and in an asset-rich model, you have multiples that are a little lower

    80% confidence
  • The NC pension system expects the wave of issuances to be well absorbed in 2026, much like it was in 2025

    80% confidence
  • Any kind of large capital expenditure cycle that we have seen over history at some point leads to the risk of overinvestment

    80% confidence
  • It's different this time, which is obviously a bit of a cliché, but for now at least, this is being approached quite prudently

    80% confidence
  • On-balance sheet debt as well as economic debt related to not-yet-begun leases should be on investors' radar as they think about risk

    80% confidence
  • Oracle pledged to raise $45 billion to $50 billion more this year, split between debt issuance and equity

    80% confidence
  • The fact that investors are comfortable taking down 30-and 40-year debt, in some cases 100-year debt, certainly suggests that investors are very comfortable that this is a balanced risk-reward opportunity

    80% confidence
  • We are incorporating these obligations and making those adjustments, particularly given the size of the leases and their growth potential. Because ultimately, in our mind, these are commitments that they have to honor. We have to effectively view them as debt when we're reviewing the credit quality of these companies

    80% confidence
  • Every company will be quite different. There will be winners and losers in this environment

    80% confidence
  • There may be some form of over investment over the next two years that leads to a correction or a growth slowdown

    80% confidence
  • The yields for the hyperscalers' bonds are near 5%, which is attractive on its own before factoring in the strong balance sheets and corporate profitability

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com